WFDC2 and cystic fibrosis: These clinical data underscore the impact of CFTR modulation therapy on decreasing HE4 plasma concentrations in CF and are in agreement with previous findings in IVA monotherapy in cases with at least one p. Gly551Asp-CFTR pathogenic variant (Nagy et al., 2019).